Surrozen (SRZN) Return on Capital Employed (2021 - 2026)
Surrozen (SRZN) recorded quarterly Return on Capital Employed of 42.93% in Q1 2026, up 11.82% quarter-over-quarter from 48.69% in Q4 2025, and down 640.0% on a YoY basis from 7.95% in Q1 2025.
Surrozen (SRZN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Surrozen's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 42.93% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 640.0% year-over-year to 42.93%; the TTM figure through Mar 2026 stood at 42.93% (down 640.0% YoY), while the FY2025 annual figure was 66.11%, down 220.0% from the prior year.
- Return on Capital Employed was 42.93% for Q1 2026 at Surrozen, up from 48.69% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 25.17% in Q2 2025 to a low of 114.48% in Q1 2024.
- Historically, Return on Capital Employed has averaged 63.3% across 5 years, with a median of 60.03% in 2023.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 5445 bps in 2024, then jumped 8681 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 54.94% in 2022, then sank by 94 bps to 106.77% in 2023, then soared by 42 bps to 62.42% in 2024, then grew by 22 bps to 48.69% in 2025, then climbed by 12 bps to 42.93% in 2026.
- The last three Return on Capital Employed figures came in at 42.93% (Q1 2026), 48.69% (Q4 2025), and 41.42% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -42.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.93% |
| Dec 31, 2025 | -48.69% |
| Sep 30, 2025 | -41.42% |
| Jun 30, 2025 | -25.17% |
| Mar 31, 2025 | -36.53% |
| Dec 31, 2024 | -62.42% |
| Sep 30, 2024 | -65.99% |
| Jun 30, 2024 | -111.98% |
| Mar 31, 2024 | -114.48% |
| Dec 31, 2023 | -106.77% |
| Sep 30, 2023 | -73.07% |
| Jun 30, 2023 | -64.87% |
| Mar 31, 2023 | -60.03% |
| Dec 31, 2022 | -54.94% |
| Sep 30, 2022 | -64.14% |
| Jun 30, 2022 | -55.94% |
| Mar 31, 2022 | -46.82% |
| Dec 31, 2021 | -41.73% |
| Sep 30, 2021 | -36.46% |
| Jun 30, 2021 | -37.94% |